AI Terminal
FARON PHARMACEUTICALS OY
Director's Dealing • Oct 14, 2020
7635_dirs_2020-10-14_3e3d6e0a-955e-4509-a75e-e38396e5716c.html
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 0989C
Faron Pharmaceuticals Oy
14 October 2020
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Grant of options
Company announcement, 14 October 2020 at 4.15 pm (EEST)
TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces that the Company's board has confirmed the grant of a total of 690,333 options over ordinary shares in the Company ("Options") under the Company's Share Option Plan 2019. The Options have been allocated under the Share Option Plan 2019 and are exercisable between 23 July 2021 and 23 July 2025 at an exercise price of €3.80 per share (£3.44), vesting 25% per annum over a period of four years. The exercise price is calculated based on the average price per share at which the ordinary shares in the Company have been traded on AIM over a period of 90 days preceding the allocation date of 23 July 2020. The amended terms of the Share Option Plan 2019 are as attached to the notice of the Company's 2020 annual general meeting, available on the Company's website, results of which were announced on 18 May 2020.
The granted 690,333 Options entitle the option holders to subscribe for a total of 690,333 new ordinary shares in the Company, if exercised in full, and represent 1.5% of the fully-diluted ordinary share capital of the Company.
Included in the number of Options granted are the following Options which were issued to directors, other persons discharging managerial responsibilities ("PDMRs"), Scientific Advisory Board ("SAB") persons closely associated with them ("PCAs") and Company personnel:
| Director | Options granted |
| Armstrong Frank | 60,000 |
| Brown Gregory | 30,000 |
| Jalkanen Markku | 120,000 |
| Manner Matti | 30,000 |
| Poulos John | 30,000 |
| Zambeletti Leopoldo | 30,000 |
| Total directors | 300,000 |
| Other PDMR | |
| Honkasalo Pessi | 12,000 |
| Hänninen Toni | 43,333 |
| Jalkanen Juho | 32,500 |
| Karvonen Matti | 32,500 |
| Lahtinen Maria | 21,000 |
| Mandelin Jami | 21,000 |
| Wichmann Yrjö | 12,000 |
| Total other PDMRs | 174,333 |
| Scientific Advisory Board | |
| Jalkanen Sirpa* | 10,000 |
| Knowles Jonathan | 10,000 |
| Curiel Tyler | 10,000 |
| Total SAB | 30,000 |
| *Jalkanen Sirpa is a person closely associated ("PCA") to Jalkanen Markku | |
| Total Company personnel | 186,000 |
For more information please contact:
Faron Pharmaceuticals Oy
Dr Markku Jalkanen, Chief Executive Officer
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner, Mark Rogers
Phone: +44 207 213 0880
Panmure Gordon (UK) Limited, Broker
Rupert Dearden
Phone: +44 207 886 2500
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen, Jussi Majamaa
Phone: +358 (0)40 555 4727
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
Email: [email protected]
Stern Investor Relations, Inc.
Julie Seidel
Phone: +1 (212) 362-1200
Email: [email protected]
About Faron Pharmaceuticals Oy
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at www.faron.com
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
Armstrong Frank
Brown Gregory
Honkasalo Pessi
Hänninen Toni
Jalkanen Juho
Jalkanen Markku
Jalkanen Sirpa
Karvonen Matti
Lahtinen Maria
Mandelin Jami
Manner Matti
Poulos John
Wichmann Yrjö
Zambeletti Leopoldo
2
Reason for notification
a.
Position/Status
Person discharging managerial responsibilities/person closely associated
b.
Initial notification/
Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
Faron Pharmaceuticals Oy
b.
LEI
7437009H31TO1DC0EB42
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument
Identification Code
Options over ordinary shares
ISIN: FI4000153309
b.
Nature of the transaction
Grant of options made pursuant to the Faron Share Option Plan 2019 exercisable at €3.80 per ordinary share
c.
Price(s) and volume(s)
Price(s)
Volume(s)
Nil
| 60,000 |
| 30,000 |
| 12,000 |
| 43,333 |
| 32,500 |
| 120,000 |
| 10,000 |
| 32,500 |
| 21,000 |
| 21,000 |
| 30,000 |
| 30,000 |
| 12,000 |
| 30,000 |
d.
Aggregated information
- Aggregated Volume
- Price
484,333
Nil
e.
Date of the transaction
13 October 2020
f.
Place of the transaction
Turku
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFFFFDLESSEFS